Humana Q1 adjusted EPS beats estimates, cuts GAAP EPS outlook

Humana

29/04/2026 11:08

Overview

US health insurer's Q1 adjusted EPS beat analyst expectations

Company affirms full-year adjusted EPS guidance, lowers GAAP EPS outlook

Q1 Medicare Advantage and state-based membership grew, aided by new contracts and acquisitions

Outlook

Humana affirms FY 2026 adjusted EPS guidance of at least $9.00

Company revises FY 2026 GAAP EPS guidance to at least $8.36 from at least $8.89

Humana expects FY 2026 Medicare Advantage membership growth of about 25% over 2025

Result Drivers

MEDICARE ADVANTAGE GROWTH - Individual Medicare Advantage membership increased, driven by new sales and improved retention from customer-led benefit strategy and service changes

CENTERWELL EXPANSION - Sequential growth in CenterWell Senior Primary Care patients, including from the MaxHealth acquisition, contributed to results

STATE-BASED CONTRACTS - Membership growth in state-based contracts was driven by new programs in Michigan, Illinois, and South Carolina

Company press release: ID:nBw8FN1WPa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
Beat
$10.31
$10.19 (25 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 20 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the managed healthcare peer group is "buy."

Wall Street's median 12-month price target for Humana Inc is $205.00, about 10.8% below its April 28 closing price of $229.72

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 21 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)